Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma
Ist Teil von
Molecular cancer therapeutics, 2019-06, Vol.18 (6), p.1025-1035
Ort / Verlag
United States
Erscheinungsjahr
2019
Link zum Volltext
Quelle
EZB Free E-Journals
Beschreibungen/Notizen
Targeting inhibitor of apoptosis proteins (IAP) with second mitochondria-derived activator of caspase (SMAC) mimetics may promote cancer cell death. We tested whether cIAP1 predicts poor prognosis in head and neck squamous cell carcinoma (HNSCC) and whether a novel Smac-mimetic, LCL161, could radiosensitize human papillomavirus-positive (HPV
) and -negative (HPV
) HNSCC. The association of
(encoding cIAP1) mRNA level with HPV status in HNSCC was analyzed using The Cancer Genome Atlas (TCGA) database. cIAP1 was assessed by IHC on an HNSCC tissue microarray (TMA,
= 84) followed by correlation analysis with HPV status and patient outcomes. Human cell culture and animal models of HNSCC were used to analyze the outcome and molecular characteristics following radiotherapy in combination with LCL161. cIAP1 expression is increased in HPV
compared with HPV
HNSCC tumors in the TCGA database. In our TMA, cIAP1 was overexpressed in HNSCC compared with normal tissues (
= 0.0003) and associated with a poor overall survival (
= 0.0402). cIAP1 levels were higher in HPV
than that in HPV
HNSCC tumors (
= 0.004) and patients with cIAP1
/HPV
HNSCC had the worst survival. LCL161 effectively radiosensitized HPV
HNSCC cells, which was accompanied with enhanced apoptosis, but not HPV
HNSCC cells. Importantly, LCL161 in combination with radiotherapy led to dramatic tumor regression of HPV
HNSCC tumor xenografts, accompanied by cIAP1 degradation and apoptosis activation. These results reveal that cIAP1 is a prognostic and a potential therapeutic biomarker for HNSCC, and targeting cIAP1 with LCL161 preferentially radiosensitizes HPV
HNSCC, providing justification for clinical testing of LCL161 in combination with radiation for patients with HPV
HNSCC.